# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnolog...
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate o...
Full Year 2023 Financial ResultsAs of December 31, 2023, the Company had $7.4 million in cash and cash equivalents, compared to...